The NM_000152.5:c.1447G>A variant in GAA is a missense variant predicted to cause substitution of glycine by arginine at amino acid 483 (p.Gly483Arg). At least 7 individuals with this variant have been reported to have Pompe disease. Of these individuals, 3 were compound heterozygous for the variant and another variant in GAA that has been classified as pathogenic by the ClinGen Lysosomal Diseases VCEP, with unknown phase, including c.2560C>T (p.Arg854Ter) (ClinVar Variation ID: 4034, SCV001371731.1) (0.5 points, PMID: 30214072, 33073009), c.525delT (ClinVar Variation ID: 4033, SCV001443331.1) (0.5 points, PMID: 33073009), and c.32-13T>G (ClinVar Variation ID: 4027) (0.5 points, PMID: 21972175, 29289479). In addition, 2 individuals were homozygous for the variant (2 x 0.5 points. PMID: 36572041, Revvity Omics Clinical Laboratory data) (PM3_Strong). Two more patients have been described with the variant and another variant, either c.-32-17_-32-10delinsT CCCTGCTGAGCCTCCTACA GGCCTCCCGC (PMID: 25687635) or c.569G>A (p.Arg190His) (PMID: 23000108). The allelic data from these patients will be used in the classification the second variant and is not included here to avoid circular logic. At least 4 individuals have GAA activity <10% normal in lymphocytes/leukocytes/muscle samples/<30% normal in cultured fibroblasts / or were reported to be on enzyme replacement therapy for Pompe disease (PMIDs: 23000108, 36572041, 33073009) (PP4_Moderate). This variant has a minor allele frequency of 0.00010(1/10306) in the African population in gnomAD v2.1.1, which is lower than the ClinGen Lysosomal Diseases VCEP threshold (<0.001) for PM2_Supporting, meeting this criterion (PM2_Supporting). Expression of the variant in COS7 cells resulted in 0% GAA activity in cells and 0% in medium, and evidence of abnormal synthesis and processing on Western blot, indicating that this variant may impact protein function (PMID: 18425781)(PS3_Moderate). The computational predictor REVEL gives a score of 0.822 which is above the thresholds predicting a damaging (>0.7) impact on GAA function and therefore meets this criterion (PS3). There is a ClinVar entry for this variant (Variation ID: 285157). In summary, this variant meets the criteria to be classified as Pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria met, based on the specification of the ClinGen Lysosomal Diseases VCEP: PS3_moderate, PM2_supporting, PM3_strong, PP3, PP4_moderate. (Classification approved by the ClinGen Lysosomal Diseases Variant Curation Expert Panel on May 7, 2024)